MDXH (MDxHealth S.A.) Gross Profit Margin

Rising demand for molecular tests in the US is expanding the target market for MDxHealth SA (MDXH). The monthly gross margin illustrates this trend, where the latest parameter stands at 58.20. MDxHealth SA (MDXH) generates revenue through prostate cancer diagnostics designed to reduce unnecessary biopsies. Business stability is supported by extensive partnerships with medical centers, which minimizes the risk of dependency on the tariffs of individual insurance organizations.
Financial and market metric breakdowns for MDxHealth SA (MDXH)

Amid aggressive competition with genetic behemoths for access to insurance reimbursements, the efficiency of MDxHealth SA depends on the control of direct diagnostic costs. This calculation subtracts the cost of goods sold from total revenue, allowing the gross margin level to assess the business's ability to maintain pricing power and protect profits from the dumping practices of large laboratories.